Skip to main
INGN
INGN logo

Inogen (INGN) Stock Forecast & Price Target

Inogen (INGN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Inogen Inc is focusing on enhancing growth through increased synergies across its sales channels and revitalizing its direct-to-consumer business while strengthening B2B relationships. The company has formed a partnership with Yuwell to penetrate the Chinese COPD market, which is approximately ten times larger than the U.S. market, indicating substantial long-term growth potential. Additionally, portable oxygen concentrators (POCs) are projected to capture 58% of the market within the next five years, further supporting a positive outlook for Inogen's operational performance and revenue generation.

Bears say

Inogen Inc has experienced a significant decline in sales across its business-to-business (B2B) and direct-to-consumer (DTC) channels, with reported decreases of 17% and 28%, respectively, in 2023. This downturn is attributed to a transition of patients from higher-paying Medicare plans to lower-reimbursing private insurance options, such as Medicare Advantage, along with an increasing number of “capped” patients whose Medicare coverage ends after 36 months. Additionally, the company has struggled with profitability due to an oversized sales force, which has compounded the negative financial outlook despite previous revenue growth.

Inogen (INGN) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inogen (INGN) Forecast

Analysts have given Inogen (INGN) a Buy based on their latest research and market trends.

According to 3 analysts, Inogen (INGN) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inogen (INGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.